Dr. Rhonda Patrick on the Joe Rogan Experience #1474, fact-checked

What the evidence shows: Patrick's figures trace to a small retrospective observational study of COVID-19 patients in the Philippines by Mark Alipio, which circulated only as an unreviewed preprint and was never published in a peer-reviewed journal; independent tracking of the vitamin D/COVID-19 preprint literature indicates it was later withdrawn from its preprint server. The study used a small, non-randomized, retrospective design with self-reported and inconsistently measured vitamin D status, making it vulnerable to confounding (for example, by age, comorbidities, and baseline health) rather than establishing that vitamin D caused the difference in outcomes. Subsequent randomized controlled trials designed to test whether vitamin D supplementation improves COVID-19 outcomes have not reproduced effects of this magnitude. A 2022 Cochrane systematic review of RCTs concluded the evidence on vitamin D as a COVID-19 treatment is highly uncertain, finding no clear benefit for mortality, ICU admission, or need for ventilation. The specific 8-fold and 20-fold risk reductions Patrick cites come from a weak, unreplicated, non-peer-reviewed observational source and are not supported by controlled trial evidence.

What the evidence shows: Patrick claimed 70% of the U.S. population has serum vitamin D levels below 30 ng/mL, calling that threshold "insufficient." NHANES-based analyses do not support a figure that high, and the 30 ng/mL cutoff itself is not the one used by the main U.S. federal reference. The Food and Nutrition Board (FNB), whose thresholds the NIH Office of Dietary Supplements cites, sets its risk-of-deficiency cutoff at below 12 ng/mL and its risk-of-inadequacy band at 12-19.6 ng/mL, considering levels of 20 ng/mL or higher generally adequate; it does not use 20 ng/mL or 30 ng/mL as the relevant cut points. Applying those FNB thresholds to NHANES 2011-2014 data, the NIH review found only about 5% of Americans age 1 and older were at risk of deficiency (below 12 ng/mL) and another 18% at risk of inadequacy (12-19.6 ng/mL), for a combined 23% below 20 ng/mL, not 70% below 30 ng/mL. A separate, more commonly cited NHANES 2005-2006 analysis (Forrest and Stuhldreher, 2011) found 41.6% of U.S. adults had levels at or below 20 ng/mL using a stricter deficiency-only cutoff, with the rate reaching 69.2% in Hispanic and 82.1% in Black subgroups specifically, not the population overall. The 30 ng/mL "insufficiency" cutoff Patrick cites reflects older Endocrine Society-style guidance rather than the FNB's federal reference values, and the NIH review notes that the Endocrine Society itself has not defined population-wide sufficiency/insufficiency/deficiency cutoffs or endorsed routine screening. Depending on the dataset, year, cutoff, and subgroup, published U.S. prevalence estimates for low vitamin D cluster in the 20-50% range; a population-wide 70% figure below 30 ng/mL is not supported by NHANES data and appears to conflate high-risk subgroup rates, an older or looser cutoff, or non-representative sourcing with the general population.

What the evidence shows: Patrick claimed obese people are roughly three times more likely to be vitamin D deficient than non-obese people. It is well established that obesity is associated with lower circulating 25-hydroxyvitamin D levels, largely because vitamin D, a fat-soluble compound, is sequestered in larger adipose tissue stores. However, the leading systematic review and meta-analysis on this topic (Pereira-Santos et al., 2015, pooling 23 observational studies) found the prevalence of vitamin D deficiency was 35% higher in obese individuals compared with normal-weight individuals (prevalence ratio 1.35, 95% CI 1.21-1.50), and 24% higher than in overweight individuals, not three times higher. The NIH Office of Dietary Supplements likewise describes people with obesity as a group at elevated risk of vitamin D inadequacy, without citing a threefold figure. Some individual studies using odds ratios rather than prevalence ratios, or specific subpopulations (e.g., severely obese bariatric-surgery candidates), report larger relative differences, but the commonly cited pooled effect size in the literature is approximately 1.2 to 1.5 times, not 3 times. The claim reflects a real and evidence-supported association but substantially overstates its magnitude.

What the evidence shows: Patrick claimed that regular vitamin C supplementation (with higher doses like 2g being more effective than 1g) reduces common cold duration by about 20% in adults and more in children. The most authoritative synthesis of the evidence, a Cochrane systematic review and meta-analysis of 31 trial comparisons (Hemila & Chalker, updated 2013), found that regular vitamin C supplementation reduced cold duration by 8% (95% CI 3-12%) in adults and by 14% (95% CI 7-21%) in children, with an 18% reduction specifically at 1-2 g/day doses in children. The review also found that taking vitamin C only after cold symptoms begin (therapeutic use, as opposed to regular daily supplementation) produced no consistent benefit on duration or severity. The 20% figure Patrick cites for adults roughly doubles the actual pooled adult estimate from the meta-analysis, though it is closer to figures reported for children at higher doses. The NIH Office of Dietary Supplements corroborates the Cochrane findings, describing the adult effect as a modest 8% reduction in duration and confirming no effect when vitamin C is started after symptoms appear.

What the evidence shows: The figures cited trace to a single prospective cohort study, the Finnish Kuopio Ischemic Heart Disease Risk Factor Study (KIHD), published in JAMA Internal Medicine in 2015 (Laukkanen et al.). In that study of 2,315 middle-aged Finnish men followed for a median of 20.7 years, those who used a sauna 4-7 times per week had a lower adjusted hazard of sudden cardiac death, fatal coronary heart disease, fatal cardiovascular disease, and all-cause mortality compared with those who used a sauna once a week; the reductions were roughly in the range Patrick cites after statistical adjustment for cardiovascular risk factors. However, this is an observational, correlational study in one demographic (middle-aged Finnish men), not a randomized controlled trial, so it cannot establish that sauna use causes lower mortality. Frequent sauna use in this population likely correlates with other health behaviors and socioeconomic factors (better fitness, higher income, healthier lifestyle) that adjustment for known covariates may not fully capture, and the finding has not been replicated in other populations or via randomized trials with hard mortality endpoints. Subsequent reviews and physiology studies through 2025-2026 continue to describe sauna bathing as associated with cardiovascular benefits in mechanistic and observational research, but characterize the evidence as suggestive rather than proof of a causal mortality benefit. The specific percentage figures are approximately consistent with the KIHD paper's results, but presenting them as an established causal effect overstates what a single observational cohort in one country and one sex can support.